Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18633336 | 0.84 | MAOB (0.54) | APPMAOB | |
| SCHEMBL228033 | 0.84 | P4HTM (0.58) | MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL5183487 | 0.82 | APP (0.56) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL16846466 | 0.82 | APP (0.66) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL15633170 | 0.81 | APP (0.54) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL1259197 | 0.81 | NPC1 (0.55) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL1258945 | 0.81 | APP (0.59) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL20000873 | 0.80 | APP (0.80) | APPMAOBNPC1RAB9APOLB | |
| SCHEMBL435691 | 0.80 | — | — | |
| SCHEMBL9545812 | 0.80 | TDP1 (0.49) | RAB9ASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368036-B1 | MACROCYCLIC PYRIDINE-N-OXIDE DERIVATIVES AS FACTOR XIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-108430471-B | Factor XIa inhibitors | 默沙东公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-11-29 | — | — | US | disclosed |
| EP-3368036-A1 | FACTOR XIA INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017074832-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017074832-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | APP 4505/4885MAOB 412/4885NPC1 3447/4885 |
| US-20180339977-A1 | FACTOR XIA INHIBITORS | F11, SERPINC1, TFPI | APP 1817/4885MAOB 830/4885NPC1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.